Jöerg Chromik

Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis

Jöerg Chromik, Charlotta Safferthal, Hubert Serve et al. · Cancer Letters · 2013 · 83 citations

Life Sciences, Cell Biology, Oncology +12

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Uwe Platzbecker, Katharina S. Götze, Philipp Kiewe et al. · Journal of Clinical Oncology · 2022 · 34 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

Tamanna Haque, Félix López Cadenas, Blanca Xicoy et al. · Leukemia Research · 2023 · 19 citations

Medicine, Pharmacology, Pharmacotherapy +6

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, Ulrich Germing, Katharina S. Götze et al. · Blood · 2016 · 15 citations

Medicine, Hematology, Pharmacotherapy +13

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced <i>TP53</i> wt acute leukemias

Eytan M. Stein, Jöerg Chromik, Daniel J. DeAngelo et al. · Cancer Research · 2017 · 11 citations

Medicine, Oncology, Pharmacology +15